stockrow
Saturday 7 November 2026
Export OCGN’s income statement to Excel — free account
Ocugen, Inc.
OCGN Healthcare Biotechnology
Ocugen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.4 million, up 8.83% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +84.9%
- Free cash flow
- −22.2%
- Total debt
- −93.7%
Quarter to September 2026, against a year earlier
0.93
0.11
+13.41%
Follow OCGN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
91.83 | 132.78 | 113.14 | 73.11 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(29.03) | (27.20) | (42.48) | (22.20) | |
P/B ratio |
0.00 | 102.13 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 105.77 | 0.00 | 0.00 | |
EV/Sales |
94.14 | 132.18 | 91.68 | 55.85 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.29) | (9.94) | (6.90) | (4.19) | |
EV/FCF |
(7.27) | (9.91) | (6.88) | (4.18) | |
Quick Ratio |
0.81 | 1.54 | 0.75 | 0.71 | |
Current Ratio |
1.06 | 1.86 | 0.80 | 0.77 | |
Net Debt/EBITDA |
(0.64) | 0.16 | 7.05 | 5.02 | |
Debt/Assets |
66.16% | 51.30% | 1.41% | 1.65% | |
Debt/Equity |
(2.37) | 5.03 | (0.11) | (0.10) | |
Asset Turnover |
0.07 | 0.07 | 0.05 | 0.06 | |
Operating CF/Net income |
0.79 | 1.14 | 0.49 | 4.37 | |
Capex/Depreciation |
(0.04) | (0.01) | (0.01) | (0.11) | |
Interest Coverage |
(12.76) | (13.51) | (3.67) | (5.75) | |
Research and Development Expense of Revenue |
(5,528.50%) | 734.18% | 718.41% | 640.70% | |
Selling, General and Administrative Expense of Revenue |
(3,177.20%) | 529.48% | 486.69% | 369.25% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
(1,037.31%) | 221.66% | 123.19% | 100.21% | |
Graham Net Nets |
(0.08) | (0.02) | (0.07) | (0.10) | |
Graham Number |
0.46 | 0.00 | 0.53 | 0.49 | |
Earnings Yield |
(17.04%) | (13.26%) | (16.99%) | (19.48%) | |
Free Cash Flow Yield |
(14.10%) | (10.05%) | (11.78%) | (18.29%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF per Share |
(0.05) | (0.07) | (0.04) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.07) | (0.04) | (0.05) | |
Cash per Share |
0.06 | 0.10 | 0.30 | 0.25 | |
Shareholders Equity per Share |
(0.04) | 0.02 | (0.05) | (0.05) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.04) | 0.02 | (0.05) | (0.05) | |
Free Cash Flow |
(14.00) | (21.80) | (12.22) | (15.89) | |
Working Capital |
1.30 | 17.84 | (26.36) | (27.47) | |
Capital Expenditures |
(0.03) | (0.01) | (0.02) | (0.15) | |
Net Current Asset Value |
(31.34) | (12.55) | (34.04) | (34.31) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.18) | 0.00 | 0.01 | 0.08 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
5.22 | 3.23 | 4.69 | 4.82 | |
Average Assets |
62.98 | 60.68 | 88.90 | 82.83 | |
Average Common Equity |
8.73 | 10.86 | (6.75) | (7.07) |
Columns are period end dates · fundamentals updated 6 Nov 2026